AJP - GI Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol (July 14, 2005). doi:10.1152/ajpgi.00243.2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/6/G1036    most recent
00243.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kolek, O. I.
Right arrow Articles by Ghishan, F. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kolek, O. I.
Right arrow Articles by Ghishan, F. K.
Submitted on May 25, 2005
Accepted on July 8, 2005

1{alpha},25-dihydroxyvitamin D3 up-regulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport

Olga I. Kolek1, Eric R. Hines2, Marci D. Jones3, Loren K. LeSueur2, Maciej A. Lipko2, Pawel R. Kiela2, James F. Collins2, Mark R. Haussler4, and Fayez K. Ghishan2*

1 Department of Pediatrics, College of Medicine, Steele Children's Research Center, University of Arizona, Tucson, AZ, USA; Department of Orthopedic Surgery, College of Medicine, Steele Children's Research Center, University of Arizona, Tucson, AZ, USA
2 Department of Pediatrics, College of Medicine, Steele Children's Research Center, University of Arizona, Tucson, AZ, USA
3 Department of Orthopedic Surgery, College of Medicine, Steele Children's Research Center, University of Arizona, Tucson, AZ, USA
4 Department of Biochemistry and Molecular Biophysics, College of Medicine, Steele Children's Research Center, University of Arizona, Tucson, AZ, USA

* To whom correspondence should be addressed. E-mail: fghishan{at}peds.arizona.edu.

Fibroblast growth factor-23 (FGF23) is a phosphaturic hormone that decreases circulating 1{alpha},25-dihydroxyvitamin D3 (1,25(OH)2D3) and elicits hypophosphatemia, both of which contribute to rickets/osteomalacia. It has been shown recently that serum FGF23 increases after treatment with the renal 1,25(OH)2D3 hormone, suggesting that 1,25(OH)2D3 negatively feedback controls its levels by inducing FGF23. To establish the tissue of origin and the molecular mechanism by which 1,25(OH)2D3 increases circulating FGF23, we administered 1,25(OH)2D3 to C57BL/6 mice. Within 24 hr, these mice displayed a dramatic elevation in serum immunoreactive FGF23, and the expression of FGF23 mRNA in bone was significantly up-regulated by 1,25(OH)2D3, but there was no effect in several other tissues. Furthermore, we treated rat UMR-106 osteoblast-like cells with 1,25(OH)2D3, and real-time PCR analysis revealed a dose- and time-dependent stimulation of FGF23 mRNA concentrations. The maximum increase in FGF23 mRNA was 1024-fold at 10-7M 1,25(OH)2D3 after 24 hr treatment, but statistically significant differences were observed as early as 4 hr after 1,25(OH)2D3 treatment. In addition, using cotreatment with actinomycin D or cycloheximide, we observed that 1,25(OH)2D3 regulation of FGF23 gene expression occurs at the transcriptional level, likely via the nuclear vitamin D receptor, and is dependent upon synthesis of an intermediary transfactor. These results indicate that bone is a major site of FGF23 expression and source of circulating FGF23 after 1,25(OH)2D3 administration, or physiologic up-regulation. Our data also establish FGF23 induction by 1,25(OH)2D3 in osteoblasts as a feedback loop between these two hormones which completes a kidney-intestine-bone axis that mediates phosphate homeostasis.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.